Standout Papers

Tumor mutational burden i... 2000 2026 2008 2017 656
  1. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer (2019)
    Alexa B. Schrock, Ching Ouyang et al. Annals of Oncology
  2. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. (2000)
    Francis M. Sirotnak, Maureen F. Zakowski et al. PubMed

Immediate Impact

5 by Nobel laureates 24 from Science/Nature 78 standout
Sub-graph 1 of 20

Citing Papers

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
2021 StandoutNature
Management of Salivary Gland Malignancy: ASCO Guideline
2021 Standout
1 intermediate paper

Works of V.A. Miller being referenced

Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies
2017
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
2000 Standout

Author Peers

Author Last Decade Papers Cites
V.A. Miller 2049 1596 502 913 83 2.9k
Andrew Weickhardt 2229 2274 506 947 107 3.2k
Helena Linardou 1765 1214 643 877 83 2.7k
Christina S. Baik 2012 1775 666 1273 112 3.4k
Vinod Ganju 1915 886 439 645 93 2.6k
Joo Hang Kim 1825 1818 417 775 89 3.0k
Vincenzo Adamo 2336 2132 673 988 115 3.7k
Vienna Ludovini 2080 1918 886 1299 101 3.4k
Davey B. Daniel 2170 2023 656 524 80 3.2k
Giovanna Finocchiaro 1579 1594 446 877 67 2.7k
Sreenivasa Nattam 1842 1030 373 755 42 2.6k

All Works

Loading papers...

Rankless by CCL
2026